ImmuneOnco Biopharmaceuticals (Shanghai) IncHKEX: 1541

Voluntary announcement - completion of capital Increase of a subsidiary

· Issued by ImmuneOnco Biopharmaceuticals (Shanghai) Inc via HKEXnews

Filed with HKEX · Stock code 1541 · · 2 pages · English

Summary by 6ix AI

This filing is a voluntary announcement regarding the completion of a capital increase of a subsidiary by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. The announcement informs shareholders and potential investors about the latest business development of the Group, confirming that the capital increase and registration procedures have been completed. The Target Company, ImmuneCare Biopharmaceutical (Shanghai) Co., Ltd., is now a non-wholly owned subsidiary engaged in the development of innovative drugs for metabolic and rare diseases.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

ImmuneOnco Biopharmaceuticals (Shanghai) Inc on 6ix

Earlier from ImmuneOnco Biopharmaceuticals (Shanghai)

Later from ImmuneOnco Biopharmaceuticals (Shanghai)

All ImmuneOnco Biopharmaceuticals (Shanghai) news releases